What the study found
The review concludes that pregnancy in familial hypercholesterolemia (FH, an inherited condition with high low-density lipoprotein cholesterol) needs careful balancing of maternal cardiovascular risk and fetal safety. It reports that heterozygous FH (one altered gene copy) does not appear to significantly raise fetal adverse outcomes, while homozygous FH (two altered gene copies) is associated with substantially higher maternal morbidity.
Why the authors say this matters
The authors say the findings matter because pregnancy in FH has unique considerations for both mother and fetus, and because treatment decisions must account for cardiovascular risk, safety, and stage of pregnancy. They also state that expanding FH pregnancy registries and prospective studies is essential to guide evidence-based care and refine recommendations.
What the researchers tested
This is a review that synthesizes current evidence, research gaps, emerging data on existing lipid-lowering strategies, and evolving guideline recommendations. The abstract says it draws on data from registries and observational studies.
What worked and what didn't
Registry and observational data indicate that HeFH does not significantly increase congenital malformation, prematurity, or low birth weight, although there may be a predisposition to early atherogenesis. The abstract says maternal risks include preeclampsia, endothelial dysfunction, and prothrombotic tendency, and that HoFH carries substantially higher morbidity. Management strategies emphasized include timely multidisciplinary care, dietary optimization, selective low-dose statin use in high-risk HoFH, and LDL apheresis for severe cases; however, statins remain contraindicated in most guidelines during pregnancy and lactation despite emerging evidence of no major teratogenic risk.
What to keep in mind
The summary describes a review rather than a new clinical trial, so its conclusions depend on the quality of the underlying registry and observational studies. It also notes research gaps and says prospective studies are still needed; limitations are not otherwise detailed in the abstract.
Key points
- HeFH in pregnancy was not found to significantly increase congenital malformation, prematurity, or low birth weight in registry and observational data.
- The abstract says HoFH is linked to substantially higher maternal morbidity.
- Maternal risks named in the review include preeclampsia, endothelial dysfunction, and a prothrombotic tendency.
- Management approaches mentioned include multidisciplinary care, dietary optimization, selective low-dose statins in high-risk HoFH, and LDL apheresis for severe cases.
- Most guidelines still contraindicate statins during pregnancy and lactation, despite emerging evidence of no major teratogenic risk.
- The authors call for more FH pregnancy registries and prospective studies.
Disclosure
- Research title:
- Familial hypercholesterolemia in pregnancy requires individualized care
- Authors:
- Jayanthi Ramanathan, D. Sullivan, Gerald Watts, Kirsten B. Holven, Yee Sian Tiong
- Institutions:
- Ng Teng Fong General Hospital, Royal Perth Hospital, Royal Prince Alfred Hospital, Royal Prince Alfred Hospital, University of Oslo
- Publication date:
- 2026-02-05
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.